Media Thread, page-17361

MOUNTAIN VIEW, Calif., February 11, 2025--(BUSINESS WIRE)--RenovoRx FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment underwritten public offering of common stock“We are very excited to close this common stock-only financing led by multiple high-quality fundamental healthcare institutional investors who are new to our company, which we view as a major achievement," said Shaun Bagai, CEO of RenovoRx. "This financing strengthens our balance sheet as we progress towards the potential realization of important valuation inflection points planned for 2025, including the recording of our first RenovoCath sales revenue, completion of enrollment for our pivotal Phase III TIGeR-PaC clinical trial, and a second interim data readout from that trial.

The support from our new institutional investors highlights their strong confidence in our patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and our clinical and commercial plans for our FDA-cleared RenovoCath delivery system. We strongly believe our technology has the potential to revolutionize cancer treatment by enabling precise delivery of therapeutic agents. We look forward to utilizing the proceeds of this offering to help make this potential a reality and drive value for our stockholders.”

Full announcement Renovo website


Note Date:Los Altos, CA and Sydney,

Australia, July 20, 2023“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene.

“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, Chief Executive Officer, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.
The ability to treat difficult-to-access tumors, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumors have been shown to limit therapy uptake.
Meanwhile back in the board rooms, Imugene who?

My opinion & PURE SPECULATION.